Avalo Q3 net income $3.2M on $14.5M license; cash $16.9M; AVTX-002 data H1 2023

Avalo Therapeutics, Inc.

2023-Q3 EPS reported -$3.39 revenue$17,155,000

Q3 net income of $3.2M vs $17.4M loss in 2021; net revenues $15M including $14.5M license revenue.
Cash $16.9M at Sep 30 2022, down $37.7M from Dec 31 2021; operating expenses fell $23.6M YTD.
Agreement to sell net economic rights to legacy out-licensed assets (AVTX-007, -501, -611) for $5M due Nov 2022.
Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma enrollment to complete by end of 2022; topline data H1 2023.
Pivotal LADDER trial of AVTX-803 in LAD II on track for data in H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Avalo Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.